Skip to content

Clinical study of subcutaneous immunotherapy of Dermatophagoides pteronyssinus in local allergic rhinitis

Clinical study of subcutaneous immunotherapy of Dermatophagoides pteronyssinus in local allergic rhinitis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000033649
Enrollment
Unknown
Registered
2020-06-07
Start date
2020-07-01
Completion date
Unknown
Last updated
2020-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

local allergic rhinitis

Interventions

experimental group: subcutaneous immunotherapy

Sponsors

The First People's Hospital of Foshan
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. 5 to 60 years old patients; 2. with persistent or intermittent nasal symptoms like nasal itch, paroxysmal sneezing, nasal watery secretion and obstruction; 3. negative results of skin prick test and serum sIgE test, positive to houst dust mite in nasal allergen provocation test. Allergens in skin prick test are house dust mite, Dermatophagoides farine tropical mite, cat dander, dog dander, cocroach, mold and pollen. The type of allergens in the serum sIgE test is the same with skin prick test.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women; 2. Severe or uncontrolled asthma, (FEV1 <70% of expected value) and irreversible obstructive airway diseases; 3. Combined with hypertension, coronary heart disease who are not suitable for adrenaline-treated diseases; 4. Severe immune diseases; 5. Severe psychological disorders or patients unable to understand the risks and limitations of treatment; 6. Malignant tumors.

Design outcomes

Primary

MeasureTime frame
symptom score;medication score;living quality score;nasal allergen provocation test;adverse effect;

Countries

China

Contacts

Public ContactQingqing Yu

81 Lingnan Avenue North, Chancheng District, Foshan, Guangdong

tommyair123@163.com+86 18038860196

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026